Circulating levels and subcutaneous adipose tissue gene expression of pigment epithelium-derived factor in polycystic ovary syndrome and normal women: A case control study

Reproductive Biology and Endocrinology

Volumn 11, Issue 1, 2013, Pages 1-7

  Lecke, Sheila B ^a,b   Morsch, Debora ^a   Spritzer, Poli M ^a,c  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Insulin resistance; mRNA; Obesity; Pigment epithelium derived factor; Polycystic ovary syndrome

Indexed keywords

COMPLEMENTARY DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIGMENT EPITHELIUM DERIVED FACTOR; RNA; TESTOSTERONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE BIOPSY; ADULT; ARTICLE; BIOPSY; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRIMAN GALLWEY SCORE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; OVULATION; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SERUM; SUBCUTANEOUS FAT; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84882671267     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-11-77     Document Type: Article

References (42)

1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010, 25:544-551. 10.1093/humrep/dep399, 19910321.
2. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004, 89:453-462. 10.1210/jc.2003-031122, 14764747.
3. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, Group PCTS. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91:48-53. 10.1210/jc.2005-1329, 16249284.
4. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010, 2010:758656. 2852606, 20396393.
5. Wiltgen D, Spritzer PM. Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes. Fertil Steril 2010, 94:2493-2496. 10.1016/j.fertnstert.2010.02.015, 20338557.
6. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1929-1935. 10.1210/jc.2004-1045, 15623819.
7. Spritzer PM, Wiltgen D. Prevalence of metabolic syndrome in patients of south of Brazil with polycystic ovary syndrome (PCOS). Arq Bras Endocrinol Metabol 2007, 51:146-147.
8. Diamanti-Kandarakis E, Spritzer PM, Sir-Petermann T, Motta AB. Insulin resistance and polycystic ovary syndrome through life. Curr Pharm Des 2012, 18:5569-5576. 10.2174/138161212803307590, 22834924.
9. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012, 18:618-637. 10.1093/humupd/dms030, 22767467.
10. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003, 4:628-636. 10.1038/nrn1176, 12894238.
11. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 1989, 30:1700-1707.
12. Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, Hino A, Jinnouchi Y, Takenaka K, Matsui T, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006, 91:2447-2450. 10.1210/jc.2005-2654, 16522692.
13. Jenkins A, Zhang SX, Gosmanova A, Aston C, Dashti A, Baker MZ, Lyons T, Ma JX. Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Res Clin Pract 2008, 82:e5-e7.
14. Borg ML, Andrews ZB, Duh EJ, Zechner R, Meikle PJ, Watt MJ. Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes 2011, 60:1458-1466. 10.2337/db10-0845, 3292318, 21464445.
15. Franck N, Gummesson A, Jernas M, Glad C, Svensson PA, Guillot G, Rudemo M, Nystrom FH, Carlsson LM, Olsson B. Identification of adipocyte genes regulated by caloric intake. J Clin Endocrinol Metab 2011, 96:E413-E418. 10.1210/jc.2009-2534, 21047925.
16. Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Inoue H. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 2009, 25:52-56. 10.1002/dmrr.820, 18677713.
17. Yamagishi S, Matsui T, Adachi H, Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol Res 2010, 61:103-107. 10.1016/j.phrs.2009.07.003, 19635565.
18. Famulla S, Lamers D, Hartwig S, Passlack W, Horrighs A, Cramer A, Lehr S, Sell H, Eckel J. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (Lond) 2011, 35:762-772.
19. Yang S, Li Q, Zhong L, Song Y, Tian B, Cheng Q, Qing H, Xia W, Luo M, Mei M. Serum pigment epithelium-derived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance. J Clin Endocrinol Metab 2011, 96:831-836. 10.1210/jc.2010-2140, 21209034.
20. Joham AE, Teede HJ, Hutchison SK, Stepto NK, Harrison CL, Strauss BJ, Paul E, Watt MJ. Pigment epithelium-derived factor, insulin sensitivity, and adiposity in polycystic ovary syndrome: impact of exercise training. Obesity (Silver Spring) 2012, 20:2390-2396.
21. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
22. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 91:456-488. 10.1016/j.fertnstert.2008.06.035, 18950759.
23. Toscani M, Migliavacca R, Sisson de Castro JA, Spritzer PM. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. Metabolism 2007, 56:992-997. 10.1016/j.metabol.2007.03.006, 17570263.
24. Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod 2009, 24:1726-1731. 10.1093/humrep/dep072, 19329517.
25. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961, 21:1440-1447. 10.1210/jcem-21-11-1440, 13892577.
26. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A.
27. Donato GB, Fuchs SC, Oppermann K, Bastos C, Spritzer PM. Association between menopause status and central adiposity measured at different cutoffs of waist circumference and waist-to-hip ratio. Menopause 2006, 13:280-285. 10.1097/01.gme.0000177907.32634.ae, 16645541.
28. WHO Physical status: the use and interpretation of anthropometry. Book Physical status: the use and interpretation of anthropometry, Volume 854 1995, 1-452. City: World Health Organization Technical Report Series, Editor ed.^eds, 1-452, WHO.
29. Lecke SB, Mattei F, Morsch DM, Spritzer PM. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril 2011, 95:2044-2049. 10.1016/j.fertnstert.2011.02.041, 21419406.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
31. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
32. Morsch DM, Carneiro MM, Lecke SB, Araujo FC, Camargos AF, Reis FM, Spritzer PM. c-fos gene and protein expression in pelvic endometriosis: a local marker of estrogen action. J Mol Histol 2009, 40:53-58. 10.1007/s10735-009-9212-7, 19199093.
33. Oliveira IO, Lhullier C, Brum IS, Spritzer PM. Gene expression of type 2 17 beta hydroxysteroid dehydrogenase in scalp hairs of hirsute women. Steroids 2003, 68:641-649. 10.1016/S0039-128X(03)00093-X, 12957669.
34. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y) 1992, 10:413-417.
35. Higuchi R, Fockler C, Dollinger G, Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y) 1993, 11:1026-1030.
36. Zipper H, Brunner H, Bernhagen J, Vitzthum F. Investigations on DNA intercalation and surface binding by SYBR Green I, its structure determination and methodological implications. Nucleic Acids Res 2004, 32:e103. 10.1093/nar/gnh101, 484200, 15249599.
37. Applied Biosystems Relative quantitation of gene expression experimental design and analysis: relative standard curve method and comparative Ct method (ΔΔCt). Guide to performing relative quantitation of gene expression using real-time quantitative PCR 2004, Foster City: Applied Biosystems, Applied Biosystems.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
39. Moreno-Navarrete JM, Touskova V, Sabater M, Mraz M, Drapalova J, Ortega F, Serrano M, Catalan V, Gomez-Ambrosi J, Ortiz MR, et al. Liver, but not adipose tissue PEDF gene expression is associated with insulin resistance. Int J Obes 2013, (15 January 2013, e-pub ahead of print).
40. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013, 28:777-784. 10.1093/humrep/des463, 23315061.
41. Wang P, Smit E, Brouwers MC, Goossens GH, van der Kallen CJ, van Greevenbroek MM, Mariman EC. Plasma pigment epithelium-derived factor is positively associated with obesity in Caucasian subjects, in particular with the visceral fat depot. Eur J Endocrinol 2008, 159:713-718. 10.1530/EJE-08-0521, 18787046.
42. Chen C, Tso AW, Cheung BM, Law LS, Ong KL, Wat NM, Janus ED, Xu A, Lam KS. Plasma concentration of pigment epithelium-derived factor is closely associated with blood pressure and predicts incident hypertension in Chinese: a 10-year prospective study. Clin Endocrinol (Oxf) 2012, 76:506-513.